Adamas Pharmaceuticals | ADMS

Adamas Pharmaceuticals Profile

  • Sector: Health Technology
  • Industry: Pharmaceuticals: Other
  • Employees: 138

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Adamas Pharmaceuticals in the news

Services We Offer

Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!

Machine Learning

Custom Scraper

Automation

Consulting